X4 Pharmaceuticals (XFOR) and Norgine announced that they have entered into an exclusive licensing and supply agreement under which Norgine will commercialize mavorixafor in Europe, Australia ...

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has commercially launched Pedmarqsi ...

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the ...